{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SABR&page=2",
    "query": {
      "intervention": "SABR",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SABR&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T09:33:10.117Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05423210",
      "title": "Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Atezolizumab + FSRT radiation",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-10-25",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05423210"
    },
    {
      "nct_id": "NCT03267368",
      "title": "Comprehensive Care Program SBRT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer",
        "Smoking",
        "Copd"
      ],
      "interventions": [
        {
          "name": "Comprehensive Care Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2017-09-11",
      "completion_date": "2018-05-23",
      "has_results": false,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 2,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03267368"
    },
    {
      "nct_id": "NCT05946213",
      "title": "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IVA Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1209,
      "start_date": "2023-12-14",
      "completion_date": "2041-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 402,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 303 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05946213"
    },
    {
      "nct_id": "NCT00856427",
      "title": "Implantation of Markers for the Radiotherapy of Lung Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "radiation therapy treatment planning/simulation",
          "type": "RADIATION"
        },
        {
          "name": "implanted fiducial-based imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2008-02",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-12-20",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856427"
    },
    {
      "nct_id": "NCT05787639",
      "title": "Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oropharynx Cancer"
      ],
      "interventions": [
        {
          "name": "Evorpacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2024-02-23",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Portland, Oregon",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05787639"
    },
    {
      "nct_id": "NCT03833154",
      "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "(Osimertinib cohort, single-arm, open-label separate cohort)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 724,
      "start_date": "2019-03-06",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 80,
      "location_summary": "Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03833154"
    },
    {
      "nct_id": "NCT07686380",
      "title": "IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "ETBX-71 Vaccine",
          "type": "DRUG"
        },
        {
          "name": "18F-DCFPyL",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2026-09-17",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07686380"
    },
    {
      "nct_id": "NCT03387085",
      "title": "QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aldoxorubicin HCl",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-051",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-061",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6207",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-6301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haNK for Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-03-19",
      "completion_date": "2024-01-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03387085"
    },
    {
      "nct_id": "NCT01392209",
      "title": "Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer",
        "MALIGNANT GLIOMA",
        "Glioblastoma",
        "Anaplastic Astrocytoma (AA)",
        "Anaplastic Oligodendroglioma (AO)",
        "Anaplastic Oligo-astrocytoma (AOA)",
        "Anaplastic Mixed Gliomas",
        "Malignant Glioma NOS"
      ],
      "interventions": [
        {
          "name": "Bevacizumab & Stereotactic Radiotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-07-08",
      "completion_date": "2019-11-15",
      "has_results": false,
      "last_update_posted_date": "2019-11-22",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Basking Ridge, New Jersey • Commack, New York + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01392209"
    },
    {
      "nct_id": "NCT03614949",
      "title": "SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Cervical Cancer Recurrent",
        "Cervical Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Stereotactic body radiation therapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2019-01-29",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-15T09:33:10.117Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Hilliard, Ohio",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Hilliard",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03614949"
    }
  ]
}